JP2012525823A - A型及びb型インフルエンザウイルス複製阻害ペプチド - Google Patents
A型及びb型インフルエンザウイルス複製阻害ペプチド Download PDFInfo
- Publication number
- JP2012525823A JP2012525823A JP2012508908A JP2012508908A JP2012525823A JP 2012525823 A JP2012525823 A JP 2012525823A JP 2012508908 A JP2012508908 A JP 2012508908A JP 2012508908 A JP2012508908 A JP 2012508908A JP 2012525823 A JP2012525823 A JP 2012525823A
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- peptide
- amino acid
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【選択図】図1b
Description
1. http://www.who.int/csr/disease/influenza/vaccinerecommendations1/en/
2. Moscona, A. N Engl J Med 353,1363-1373 (2005).
3. Davies, W.L. et al. Science 144,862-863 (1964).
4. Moscona, A. N Engl J Med 360, 953-956(2009).
5. Dharan, N.J. et al. JAMA 301,1034-1041 (2009).
6. Pilger, B.D, Cui, C. & Coen, D.M.Chem Biol 11, 647-654 (2004).
7. Brownlee, GG. & Sharps, J.L. JVirol 76, 7103-7113 (2002).
8. Perales, B. & Ortin, J. J Virol71, 1381-1385 (1997).
9. Fodor, E. et al. J Virol 76,8989-9001 (2002).
10. He, X. et al. Nature 454, 1123-1126(2008).
11. Obayashi, E. et al. Nature 454,1127-1131 (2008).
12. Ghanem, A. et al. J Virol 81,7801-7804 (2007).
13. Dostmann, W.R. et al. Proc Natl AcadSci USA 97, 14772-14777 (2000).
14. Chokephaibulkit, K. et al. PediatrInfect Dis J 24, 162-166 (2005).
15. Norton, G.P. et al. Virology 156,204-213 (1987).
16. Schwemmle, M, Weining, K.C, Richter,M.F, Schumacher, B. & Staeheli, P. Virology 206, 545-554 (1995).
17. Mayer, D. et al. J Proteome Res 6,672-682 (2007).
18. Pleschka, S. et al. J Virol 70,4188-4192 (1996).
19. Schneider, U., Naegele, M.,Staeheli, P. & Schwemmle, M. J Virol 77, 11781-11789 (2003).
20. Schmidtke, M., Schnittler, U., Jahn,B., Dahse, H. & Stelzner, A. J Virol Methods 95, 133-143 (2001).
21. Edgar, R.C. Nucleic Acids Res 32,1792-1797 (2004).
Claims (17)
- A型及びB型の両インフルエンザウイルスのヘテロ三量体ウイルスRNAポリメラーゼ複合体のPA及びPB1サブユニットの間のタンパク質−タンパク質相互作用を競合的に阻害する合成又は単離されたインフルエンザウイルス複製阻害ペプチドであって、配列X5X6X7X8X9X10を含むアミノ酸配列を含み、X5はPであり、X6はT、Y、F、W、H、C、I、L、V、A又はMであり、X7はL又はFであり、X8はL、I、F又はMであり、X9はF、Y、W、H、L、R又はSであり、X10はL、I又はYであり、前記アミノ酸配列がMDVNPTLLFLKである野生型PB11−11Aによるポリペプチドと少なくとも60%、好ましくは少なくとも70%、より好ましくは少なくとも80%又は90%同一であり、前記野生型PB11−11Aは除外される、インフルエンザウイルス複製阻害ペプチド。
- MDVNPTLLFLKVPAQである野生型PB11−15Aによるポリペプチドと少なくとも66%、好ましくは少なくとも73%、より好ましくは少なくとも79%、86%又は93%同一なアミノ酸配列を含み、前記野生型PB11−15Aは除外される、請求項1に記載のペプチド。
- アミノ酸配列X6X7X8X9X10を含み、X6がT、Y、F、W、H、C、I、L又はVであり、X7がL又はFであり、X8がL又はIであり、X9がF、Y又はWであり、X10がLである、請求項1又は2に記載のペプチド。
- アミノ酸配列X6X7を含み、X6がT、Y、F、W、H、C、I、L又はVであり、X7がL又はFである、請求項3に記載のペプチド。
- 前記アミノ酸配列が15残基のX1−15を含む、請求項1〜4のいずれか一項に記載のペプチド。
- アミノ酸配列MDVNPX6X7LFLKVPAQを含み、X6がT、Y、F、W、H、C、A、I、L、V又はMの群より選択され、X7がL又はFの群より選択される、請求項1〜5のいずれか一項に記載のペプチド。
- MDVNPYFLFLKVPAQ、MDVNPYLLFLKVPAQ、MDVNPWLLFLKVPAQ又はMDVNPFLLFLKVPAQの群から選択されるアミノ酸配列を含む、請求項6に記載のペプチド。
- 細胞透過性ペプチド、好ましくはHIV−Tatの細胞透過性ドメインに融合した請求項1〜7のいずれか一項に記載のペプチドを有効成分として含むインフルエンザウイルス複製阻害剤。
- A型インフルエンザ株及びB型インフルエンザ株の複製を阻害する、請求項8に記載のインフルエンザウイルス複製阻害剤。
- 請求項1〜7のいずれか一項に記載のペプチドを有効成分として含むインフルエンザ予防/治療剤。
- A型インフルエンザ株及びB型インフルエンザ株に対して有効である、請求項10に記載のインフルエンザ予防/治療剤。
- 請求項1〜7のいずれか一項に記載のペプチドをコードするポリヌクレオチド。
- 請求項1〜7のいずれか一項に記載のペプチド及び適合性の担体を含むガレヌス製剤。
- 請求項1〜7のいずれか一項に記載のペプチドを含む医薬。
- インフルエンザの治療に用いるための、請求項1〜7のいずれか一項に記載のペプチド。
- インフルエンザを治療する医薬の製造のための、請求項1〜7のいずれか一項に記載のペプチドの使用。
- 好ましくは競合的阻害剤としての、前記野生型を包含する請求項1〜7のいずれか一項に記載のペプチドの使用を含む、インフルエンザポリメラーゼサブユニットの相互作用の阻害剤をELISA又は蛍光偏光アッセイに基づいて決定する方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/055632 WO2010127712A1 (en) | 2009-05-08 | 2009-05-08 | Influenza a and b virus replication-inhibiting peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012525823A true JP2012525823A (ja) | 2012-10-25 |
Family
ID=41682564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012508908A Pending JP2012525823A (ja) | 2009-05-08 | 2009-05-08 | A型及びb型インフルエンザウイルス複製阻害ペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120129764A1 (ja) |
EP (1) | EP2427478A1 (ja) |
JP (1) | JP2012525823A (ja) |
CN (1) | CN102439028A (ja) |
WO (1) | WO2010127712A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119377A1 (en) * | 2012-02-11 | 2013-08-15 | Board Of Regents, The University Of Texas System | Autophagy-inducing peptide |
CN102617712B (zh) * | 2012-03-29 | 2014-03-05 | 中国科学院生物物理研究所 | 有效抑制流感病毒聚合酶活性的多肽 |
CN102690335B (zh) * | 2012-05-21 | 2013-10-16 | 中国科学院生物物理研究所 | 有效抑制流感病毒聚合酶活性的多肽 |
CA3029784A1 (en) * | 2016-07-07 | 2018-01-11 | The European Molecular Biology Laboratory | Viral polypeptide fragments that bind cellular pol ii c-terminal domain (ctd) and their uses |
CN109966497B (zh) * | 2019-04-08 | 2021-03-12 | 中国医学科学院医药生物技术研究所 | 以ipan或其编码基因为靶点的物质在制备流感病毒抑制剂中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778847B2 (en) * | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
-
2009
- 2009-05-08 EP EP09779435A patent/EP2427478A1/en not_active Withdrawn
- 2009-05-08 US US13/318,769 patent/US20120129764A1/en not_active Abandoned
- 2009-05-08 CN CN2009801591913A patent/CN102439028A/zh active Pending
- 2009-05-08 WO PCT/EP2009/055632 patent/WO2010127712A1/en active Application Filing
- 2009-05-08 JP JP2012508908A patent/JP2012525823A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN102439028A (zh) | 2012-05-02 |
EP2427478A1 (en) | 2012-03-14 |
WO2010127712A1 (en) | 2010-11-11 |
US20120129764A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moisy et al. | HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication | |
Ghanem et al. | Peptide-mediated interference with influenza A virus polymerase | |
Wunderlich et al. | Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication | |
Badani et al. | Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity | |
Münch et al. | Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide | |
EP2247606B1 (en) | Compositions and methods for the treatment of viral infections | |
Strack et al. | Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis | |
ES2655289T3 (es) | Polipéptido antagonista del receptor 4 de quimioquina CXC (CXCR-4) | |
CN102256615A (zh) | 拟肽大环化合物 | |
York et al. | An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion | |
Guu et al. | Mapping the domain structure of the influenza A virus polymerase acidic protein (PA) and its interaction with the basic protein 1 (PB1) subunit | |
Reuther et al. | Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences | |
JP2012525823A (ja) | A型及びb型インフルエンザウイルス複製阻害ペプチド | |
Doyle et al. | Two domains that control prefusion stability and transport competence of the measles virus fusion protein | |
Ha et al. | Mutations in the fusion protein of measles virus that confer resistance to the membrane fusion inhibitors carbobenzoxy-d-Phe-l-Phe-Gly and 4-nitro-2-phenylacetyl amino-benzamide | |
Yu et al. | Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants | |
Lin et al. | A “building block” approach to the new influenza A virus entry inhibitors with reduced cellular toxicities | |
Manna et al. | Fusion protein targeted antiviral peptides: fragment-based drug design (FBDD) guided rational design of dipeptides against SARS-CoV-2 | |
Wanitchang et al. | Influenza B virus M2 protein can functionally replace its influenza A virus counterpart in promoting virus replication | |
US11186614B2 (en) | Anti-HIV peptides | |
US20120122896A1 (en) | 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication | |
Li et al. | Murine leukemia virus R peptide inhibits influenza virus hemagglutinin-induced membrane fusion | |
US20200231939A1 (en) | Assay and medicament | |
Tada et al. | A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture | |
JP6570448B2 (ja) | インフルエンザウイルス阻害薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140304 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140310 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140311 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140909 |